The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.
Y. Y. Janjigian
Consultant or Advisory Role - Genentech
Research Funding - Boehringer Ingelheim
H. J. Groen
No relevant relationships to disclose
L. Horn
No relevant relationships to disclose
E. F. Smit
No relevant relationships to disclose
Y. Fu
Employment or Leadership Position - Boehringer Ingelheim
F. Wang
Employment or Leadership Position - Boehringer Ingelheim
M. Shahidi
Employment or Leadership Position - Boehringer Ingelheim
L. J. Denis
Employment or Leadership Position - Boehringer Ingelheim
W. Pao
Consultant or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MolecularMD; Symphony Evolution
Research Funding - AstraZeneca; Enzon
Other Remuneration - Rights to testing of EGFR T790M were licensed on my behalf and others by MSK to Molecular MD
V. A. Miller
Consultant or Advisory Role - Argole Systems; Boehringer Ingelheim; Genentech; Lilly; OSI Pharmaceuticals; Pfizer; Roche
Research Funding - Boehringer Ingelheim; Genentech; OSI Pharmaceuticals; Pfizer